Regulatory Updates

PDMI keeps a close watch on governmental updates potentially impacting 340B providers. Specifically, the Prescription Drug Pricing Reduction Act, is a source of constant oversight and review by our internal team. “We always have an ear to the ground on these regulatory matters, since we are committed to doing all we can in support of protecting the covered entities under 340B. Making sure our clients have the ability to offer their most at-risk/in-need patients the prescriptions they need regardless of an ability to pay for them is central to all that we do,” said Tom Bielawski, Director of PDMI’s 340B program.

You can find a one-one-one interview with Tom here.